DOCSLIB.ORG

Activation of Bitter Taste Receptors (Tas2rs) Relaxes Detrusor Smooth Muscle and Suppresses Overactive Bladder Symptoms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Activation of Bitter Taste Receptors (Tas2rs) Relaxes Detrusor Smooth Muscle and Suppresses Overactive Bladder Symptoms www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 16 Activation of bitter taste receptors (tas2rs) relaxes detrusor smooth muscle and suppresses overactive bladder symptoms Kui Zhai1,*, Zhiguang Yang1,*, Xiaofei Zhu2,*, Eric Nyirimigabo1, Yue Mi3, Yan Wang4, Qinghua Liu5, Libo Man2, Shiliang Wu3, Jie Jin3 and Guangju Ji1 1 National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China 2 Department of Urology, Beijing Jishuitan Hospital, Beijing, China 3 Department of Urology, National Research Center for Genitourinary Oncology, Peking University First Hospital and Institute of Urology, Beijing, China 4 Department of Gastroenterology, Peking University First Hospital, Beijing, China 5 Institute for Medical Biology, College of Life Sciences, South-Central University for Nationalities, Wuhan, China * Those authors have contributed equally to this work Correspondence to: Guangju Ji, email: [email protected] Correspondence to: Jie Jin, email: [email protected] Keywords: bitter taste receptors, chloroquine, detrusor smooth muscle, human, mouse, overactive bladder, Gerotarget Received: March 10, 2016 Accepted: March 20, 2016 Published: April 02, 2016 ABSTRACT Bitter taste receptors (TAS2Rs) are traditionally thought to be expressed exclusively on the taste buds of the tongue. However, accumulating evidence has indicated that this receptor family performs non-gustatory functions outside the mouth in addition to taste. Here, we examined the role of TAS2Rs in human and mouse detrusor smooth muscle (DSM). We showed that mRNA for various TAS2R subtypes was expressed in both human and mouse detrusor smooth muscle (DSM) at distinct levels. Chloroquine (CLQ), an agonist for TAS2Rs, concentration-dependently relaxed carbachol- and KCl-induced contractions of human DSM strips. Moreover, 100 µM of CLQ significantly inhibited spontaneous and electrical field stimulation (EFS)-induced contractions of human DSM strips. After a slight contraction, CLQ (1 mM) entirely relaxed carbachol-induced contraction of mouse DSM strips. Furthermore, denatonium and quinine concentration-dependently decreased carbachol-induced contractions of mouse DSM strips. Finally, we demonstrated that CLQ treatment significantly suppressed the overactive bladder (OAB) symptoms of mice with partial bladder outlet obstruction (PBOO). In conclusion, we for the first time provide evidence of the existence of TAS2Rs in the urinary DSM and demonstrate that TAS2Rs may represent a potential target for OAB. These findings open a new approach to develop drugs for OAB in the future. INTRODUCTION reported that the overall prevalence of OAB syndrome was 11.8%; rates were similar between men and women [3]. The urinary bladder is the organ that collects urine The prevalence of OAB syndrome increased with age in excreted from kidneys before disposal by urination. a linear fashion [3-5]. As a result, in patients over the age Bladder dysfunction, such as overactive bladder (OAB), of 65 years the prevalence of OAB syndrome can increase has serious effects on quality of life [1]. OAB syndrome to 30.9% [4]. Anticholinergic drugs remain the first-line is a common condition characterized by the presence pharmacologic treatment for OAB syndrome [6] despite of urgency with or without incontinence, frequency, producing undesirable side effects such as dry mouth, and nocturia. The etiology of OAB syndrome is very constipation, and blurred vision [7]. It is estimated that complicated and includes increased afferent activity, by 2018, more than 500 million people worldwide will decreased inhibitory control, and increased sensitivity of be affected by OAB [3, 8]. Thus, it is of great urgency to the detrusor muscle to efferent stimulation [2]. It has been identify novel targets for this disorder. www.impactjournals.com/oncotarget 21156 Oncotarget Bitter taste receptors (TAS2Rs) belong to the obstruction (PBOO). superfamily of G-protein-coupled receptors (GPCRs) [9]. GPCRs, which convert extracellular stimuli RESULTS into intracellular signals through the activation of heterotrimeric G-proteins, are involved in many diseases and are also the target of approximately 40% of all modern Expression profile of Tas2rs in human DSM medicinal drugs [10]. However, these targeted GPCRs are only a small part of this receptor superfamily and over 30% GPCRs have no known endogenous ligand, Using quantitative reverse transcription PCR (RT- indicating that many potential targets remain to be qPCR), we screened the expression profile of all 25 discovered [11]. As TAS2Rs are traditionally thought to TAS2R genes in human DSM. As shown in Figure 1, we be expressed exclusively on the taste buds of the tongue, found that TAS2R7 and TAS2R8 were the most abundantly they have been generally neglected as drug targets. expressed genes, with levels similar to the reference However, accumulating evidence has indicated that this gene glyceraldehyde 3-phosphate dehydrogenase receptor family performs non-gustatory functions outside (GAPDH). The expression levels of TAS2R1, TAS2R5, the mouth in addition to taste. We and others have shown TAS2R9, TAS2R13, TAS2R20, and TAS2R31 were two that TAS2Rs are expressed in both human and mouse orders of magnitude lower than that of GAPDH with airway smooth muscle and mediate the tone of airway the following rank order: TAS2R13 > TAS2R1≈TAS2R9 smooth muscle [12-15]. Besides, it has been reported that > TAS2R5≈TAS2R20≈TAS2R31. TAS2R4, TAS2R10, this receptor family plays a critical role in the heart [16], TAS2R14, TAS2R30, TAS2R38, TAS2R39, TAS2R40, thyroid [17], and gastrointestinal muscle [18]. However, TAS2R45, and TAS2R50 were very slightly detected. Eight their role in the urinary bladder has never been determined. TAS2R genes (TAS2R3, TAS2R16, TAS2R19, TAS2R41, In this study, we examined the expression and TAS2R42, TAS2R43, TAS2R46, and TAS2R60) were not function of TAS2Rs in human and mouse urinary detrusor expressed. smooth muscle (DSM). We further determined their role in the urinary bladder of mice with partial bladder outlet Figure 1: The genes of TAS2R are expressed in human DSM. RT-qPCR screen of TAS2R genes in human DSM. Data were presented as relative expression of TAS2R genes to the reference gene GAPDH (mean ± SEM of 5 independent DSM samples). Of all 25 human TAS2R gens, 17 TAS2Rs were expressed in human DSM with distinct levels, whereas 8 TAS2Rs were not detected. www.impactjournals.com/oncotarget 21157 Oncotarget Chloroquine (CLQ) relaxes human DSM strips on these contractions (Figure 2B and 2D). Moreover, we investigated the effects of CLQ on the nerve-evoked contractions induced by a wide range of electrical field Next, we determined the function of TAS2Rs in stimulation (EFS) frequencies as described from Petkov’s human DSM with chloroquine (CLQ). CLQ is an agonist work [25]. We first applied increasing EFS frequencies of TAS2Rs and has been shown to activate several (0.5-50 Hz) as a control protocol, followed by the addition TAS2Rs, including TAS2R3, TAS2R7, TAS2R10, and of 100 µM CLQ (Figure 3E). Five minutes after the TAS2R39 [19-21]. We showed that CLQ did not exhibit addition, a second EFS protocol was applied. As shown any effects on the base tone of human DSM strips. We in Figure 3F, CLQ (100 µM) significantly decreased the thus tested the effect of CLQ on carbachol- and KCl- amplitudes of EFS-induced contractions within a wide induced contractions of human DSM strips according range (0.5 Hz, 2 Hz, 3.5 Hz, 5 Hz, 7.5 Hz, 10 Hz, 12.5 to previous studies [22-24]. We showed that cumulative Hz, 15 Hz, 20 Hz, 30 Hz, 40 Hz, and 50 Hz) by 21 ± concentrations of CLQ (100 nM to 3 mM) induced 12%, 52 ± 15%, 26 ± 14%, 32 ± 10%, 31 ± 10%, 40 ± significant decreases of carbachol- and KCl-induced 5%, 50 ± 8%, 55 8%, 46 ± 10%, 48 ± 13%, and 57 ± 19%, contractions in a concentration-dependent manner (Figure respectively. Of all the strips (n = 26), only three exhibited 2A-2D). In contrast, the vehicle had no significant effects Figure 2: Effect of chloroquine on stimulus-induced and spontaneous contractions of human DSM strips. A., B. Original trace and summary data showing the effects of vehicle (control, n = 4 strips) or chloroquine (CLQ: 100 nM to 3 mM; n = 5 strips) on carbachol-induced contractions. C., D. Original trace and summary data showing the effects of vehicle (control, n = 4 strips) or CLQ (100 nM to 3 mM; n = 5 strips) on KCl-induced contractions. E., F. Original trace and summary data showing the effects of CLQ (100 µM) on EFS-induced contractions (n= 4 strips). G. Original trace of spontaneous contractions in the absence and presence of 100 µM CLQ. Data are mean ± SEM of n independent DSM strips. *p < 0.05, **p < 0.01, and***p < 0.001 as indicated. www.impactjournals.com/oncotarget 21158 Oncotarget Figure 3: The genes of Tas2r are expressed in mouse DSM. RT-qPCR screen of Tas2r genes in mouse DSM. Data were presented as relative expression of Tas2r genes to the reference gene Gapdh (mean ± SEM of 3 independent DSM samples). Of all 35 mouse Tas2r genes, 19 Tas2rs were expressed in mouse DSM with distinct levels, whereas 16 Tas2rs were not detected. Figure 4: Effect of bitter tastants on carbachol-induced contractions of mouse DSM strips. A.-C. Original traces and summary data showing the effects of vehicle (control, n = 5 strips) or chloroquine (CLQ: 1 mM; n = 6 strips) on carbachol-induced contractions in mouse DSM strips. D. Original trace showing the effects of denatonium (100 nM to 3 mM) on carbachol-induced contractions. E. Original trace showing the effects of quinine (100 nM to 3 mM) on carbachol-induced contractions. F. Summary data showing the effects of vehicle, denatonium (n = 5 strips), and quinine (n = 5 strips) on carbachol-induced contractions. Data are mean ± SEM of n independent mouse DSM strips. *p < 0.05, **p < 0.01, and ***p < 0.001 were control vs. CLQ or denatomium; #p < 0.05, ##p < 0.01, and ###p < 0.001 were control vs. quinine, respectively.
Load more

Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Genetic Association with Overall Survival of Taxane-Treated Lung
    Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Niu, Nifang et al. “Genetic Association with Overall Survival of Taxane-treated Lung Cancer Patients - a Genome-wide Association Study in Human Lymphoblastoid Cell Lines Followed by a Clinical Association Study.” BMC Cancer 12.1 (2012): 422. CrossRef. Web. As Published http://dx.doi.org/10.1186/1471-2407-12-422 Publisher BioMed Central Ltd. Version Final published version Citable link http://hdl.handle.net/1721.1/77191 Terms of Use Creative Commons Attribution Detailed Terms http://creativecommons.org/licenses/by/2.0 Genetic variations and paclitaxel response Supplementary Figure 1. Imputation analysis for 8 SNPs associated with both paclitaxel IC50 in LCLs and overall survival in lung cancer patients. SNPs within 200kb up-/downstream of those 8 SNPs were imputed. Black circles indicate SNPs observed by genotyping, while red triangles indicate imputed SNPs. The y-axis represents –log10(p-value) for the association of each SNP with paclitaxel IC50, and the x-axis represents the chromosomal locations of the SNPs. Genetic variations in paclitaxel response 1 Supplementary Table 1. Top 1415 SNPs that were associated with paclitaxel IC50 with p-values <10-3 and top 147 SNPs that were significantly associated with paclitaxel IC50
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • TAS2R20 Variants Confer Dietary Adaptation to High-Quercitrin Bamboo Leaves in Qinling Giant Pandas
    TAS2R20 variants confer dietary adaptation to high-quercitrin bamboo leaves in Qinling giant pandas Xiangxu Hu1, Guan Wang2, Lei Shan3, Shuyan Sun1, Yibo Hu1, and Fuwen Wei1 1Institute of Zoology Chinese Academy of Sciences 2Affiliation not available 3Nanjing Normal University College of Life Sciences May 5, 2020 Abstract Abstract: Sensitivity to bitter tastes provides animals with an important means of interacting with their environment and thus, influences their dietary preferences. Genetic variants encoding functionally distinct receptor types contribute to variation in bitter taste sensitivity. Our previous study showed that two nonsynonymous sites, A52V and Q296H, in the TAS2R20 gene are directionally selected in giant pandas from the Qinling Mountains, which are speculated to be the causative base-pair changes of Qinling pandas for the higher preference for bamboo leaves in comparison with other pandas. Here, we used functional expression in engineered cells to identify agonists of pTAS2R20 (i.e. giant panda's TAS2R20) and interrogated the differences in perception in the in vitro responses of pTAS2R20 variants to the agonists. Our results show that pTAS2R20 is specifically activated by quercitrin and that pTAS2R20 variants exhibit differences in the sensitivity of their response to the agonist. Compared to pTAS2R20 in pandas from other areas, the receptor variant with A52V and Q296H, which is most commonly found in Qinling pandas, confers a significantly decreased sensitivity to quercitrin. We subsequently quantified the quercitrin content of the leaves of bamboo distributed in the Qinling Mountains, which was found to be significantly higher than that of the leaves of bamboo from panda habitats in other areas.
    [Show full text]
  • LETTER Doi:10.1038/Nature09515
    LETTER doi:10.1038/nature09515 Distant metastasis occurs late during the genetic evolution of pancreatic cancer Shinichi Yachida1*, Siaˆn Jones2*, Ivana Bozic3, Tibor Antal3,4, Rebecca Leary2, Baojin Fu1, Mihoko Kamiyama1, Ralph H. Hruban1,5, James R. Eshleman1, Martin A. Nowak3, Victor E. Velculescu2, Kenneth W. Kinzler2, Bert Vogelstein2 & Christine A. Iacobuzio-Donahue1,5,6 Metastasis, the dissemination and growth of neoplastic cells in an were present in the primary pancreatic tumours from which the meta- organ distinct from that in which they originated1,2, is the most stases arose. A small number of these samples of interest were cell lines common cause of death in cancer patients. This is particularly true or xenografts, similar to the index lesions, whereas the majority were for pancreatic cancers, where most patients are diagnosed with fresh-frozen tissues that contained admixed neoplastic, stromal, metastatic disease and few show a sustained response to chemo- inflammatory, endothelial and normal epithelial cells (Fig. 1a). Each therapy or radiation therapy3. Whether the dismal prognosis of tissue sample was therefore microdissected to minimize contaminat- patients with pancreatic cancer compared to patients with other ing non-neoplastic elements before purifying DNA. types of cancer is a result of late diagnosis or early dissemination of Two categories of mutations were identified (Fig. 1b). The first and disease to distant organs is not known. Here we rely on data gen- largest category corresponded to those mutations present in all samples erated by sequencing the genomes of seven pancreatic cancer meta- from a given patient (‘founder’ mutations, mean of 64%, range 48–83% stases to evaluate the clonal relationships among primary and of all mutations per patient; Fig.
    [Show full text]
  • Ep 2329271 B1
    (19) & (11) EP 2 329 271 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G01N 33/566 (2006.01) G01N 33/50 (2006.01) 20.06.2012 Bulletin 2012/25 (86) International application number: (21) Application number: 09775777.7 PCT/CH2009/000290 (22) Date of filing: 27.08.2009 (87) International publication number: WO 2010/022529 (04.03.2010 Gazette 2010/09) (54) METHODS TO IDENTIFY MODULATORS VERFAHREN ZUR IDENTIFIZIERUNG VON MODULATOREN PROCÉDÉS D’IDENTIFICATION DE MODULATEURS (84) Designated Contracting States: • EVANS PENNIMPEDE, Jenny Ellen AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Cincinnati, OH 45241 (US) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR (74) Representative: Simmons, John Murray Givaudan Schweiz AG (30) Priority: 29.08.2008 US 92839 P Global Patents Überlandstrasse 138 (43) Date of publication of application: 8600 Dübendorf (CH) 08.06.2011 Bulletin 2011/23 (56) References cited: (73) Proprietor: Givaudan SA WO-A2-2006/053771 WO-A2-2006/086150 1214 Vernier (CH) WO-A2-2007/011859 US-A1- 2004 214 239 US-A1- 2008 038 739 (72) Inventors: • SLACK, Jay, Patrick Loveland, OH 45140 (US) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Reyna Alejandra Jiménez Flores
    TESIS DOCTORAL Actividad citotóxica del éter-lípido edelfosina en células de cáncer de hígado. Reyna Alejandra Jiménez Flores Director de tesis: Faustino Mollinedo García CENTRO DE INVESTIGACIÓN DEL CÁNCER UNIVERSIDAD DE SALAMANCA – CSIC SALAMANCA 2015 El Dr. Faustino Mollinedo García, Profesor de Investigación del Consejo Superior de Investigaciones Científicas (CSIC) y miembro del Instituto de Biología Molecular y Celular del Cáncer de la Universidad de Salamanca. CERTIFICA: Que la memoria de tesis titulada “Actividad citotoxica del éter‐lípido edelfosina en células de cáncer de hígado” presentado por Dña. Reyna Alejandra Jiménez Flores, ha sido realizada bajo su dirección en el Instituto de Biología Molecular y Celular del Cáncer y reúne, a su juicio, originalidad y contenidos suficientes para que sea presentada ante el tribunal correspondiente y optar al grado de Doctor por la Universidad de Salamanca. Y para que así conste, a efectos legales, expide el presente certificado en Salamanca, a 16 de noviembre de 2015. Dr. Faustino Mollinedo García Director de la tesis A mis padres y a mi hermana A Paula y a David FIDES No te resignes antes de perder definitiva, irrevocablemente La batalla que libras. Lucha erguido y sin contar las enemigas huestes. ¡Mientras veas resquicios de esperanza, no te rindas!. La suerte gusta de acumular los imposibles para vencerlos en conjunto, siempre, con el fatal y misterioso golpe de su masa de Hércules.... ¿Sabes tu si el instante en que, ya fatigado, desesperes, es justo aquel que a la definitiva realización de tu ideal precede?. Quien alienta una fe tenaz, al hado más torvo compromete en su favor.
    [Show full text]
  • Supplementary Tables Supplemental Table S1: Comparison of the Coverage of Reference Panels Used for SNP Imputation. the Markers
    Supplementary Tables Supplemental Table S1: Comparison of the coverage of reference panels used for SNP imputation. The markers on the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA) reference panel and Haplotype Reference Consortium (HRG) used to impute SNPs from our AA and CAU participants were compared to one thousand genomes (1kG) dataset. Loci information CAAPA vs 1kG HRC vs 1kG Total loci 45,639,158 90,558,388 Overlapping loci 24,880,301 49,826,569 Percent overlap 54.52% 55.02% 1kG-only loci 9,363,544 15,148,191 Ref-only loci 8,461,186 22,649,501 Supplemental Table S2: SNP imputation results. The total number of SNPs imputed for the AA and CAU participants either using the Michigan imputation server (Minimac) or Beagle. Targets prepared for: AA CAU Beagle 730,616 726,165 Minimac 698,343 660,733 Supplemental Table S3: Allele frequencies of TA2R38 SNPs by each ancestral group and time point. The rs number of each SNP, the location of SNP buy chromosome (CHR) and base pair position (POS) is provided along with the allele frequency (ALLELE:FREQ) for each SNP. Baseline 6-month Baseline 6-month AA (N = 297) AA (N = 234) CAU (N = 198) CAU (N = 151) SNP CHR POS ALLELE:FREQ ALLELE:FREQ ALLELE:FREQ ALLELE:FREQ rs10246939 7 141672604 T:0.49 C:0.51 T:0.50 C:0.50 T:0.54 C:0.46 T:0.54 C:0.46 rs1726866 7 141672705 G:0.68 A:0.32 G:0.68 A:0.32 G:0.46 A:0.54 G:0.46 A:0.54 rs713598 7 141673345 C:0.50 G:0.50 C:0.50 G:0.50 C:0.58 G:0.42 C:0.58 G:0.42 Supplemental Table S4: Linkage disequilibrium analysis of TAS2R38 SNPs at each time point of the intervention.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,347,934 B2 Shekdar Et Al
    USOO9347934B2 (12) United States Patent (10) Patent No.: US 9,347,934 B2 Shekdar et al. (45) Date of Patent: May 24, 2016 (54) ASSAYS FOR IDENTIFYING COMPOUNDS 2008, OO38739 A1 2/2008 Li et al. THAT MODULATE BITTERTASTE 2008/0167286 A1* 7/2008 Gopalakrishnan et al. ........................ 514,21016 (71) Applicants: CHROMOCELL CORPORATION, 2010/01298.33 A1* 5/2010 Brune et al. ................. 435/721 North Brunswick, NJ (US); KRAFT FOODS GROUP BRANDS LLC, FOREIGN PATENT DOCUMENTS Northfield, IL (US) CN 1341632 A 3, 2002 CN 101583717 A 11, 2009 (72) Inventors: Kambiz Shekdar, New York, NY (US); CN 101828.111 A 9, 2010 Purvi Manoj Shah, Bridgewater, NJ WO WO-0038536 A2 7, 2000 WO WO-2004O29087 4/2004 (US); Joseph Gunnet, Flemington, NJ WO WO-2006053771 A2 5, 2006 (US); Jane V. Leland, Wilmette, IL WO WO-2007002026 A2 1/2007 (US); Peter H. Brown, Glenview, IL WO WO-2008057470 5, 2008 (US); Louise Slade, Morris Plains, NJ WO WO-2008119.195 A1 10, 2008 (US) WO WO-20081191.96 10, 2008 WO WO-20081191.97 10, 2008 (73) Assignees: Chromocell Corporation, North W WSi. A2 1929 Brunswick, NJ (US); Kraft Foods WO WO-2010O886.33 8, 2010 Group Brands LLC, Northfield, IL WO WO-2010O99983 A1 9, 2010 (US) WO WO-2013022947 2, 2013 (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. Bachmanov et al., Taste Receptor Genes, 2007, 27:389-414.* Behrens et al., Structural Requirements for Bitter Taste Receptor (21) Appl.
    [Show full text]
  • Curcumin Alters Gene Expression-Associated DNA Damage, Cell Cycle, Cell Survival and Cell Migration and Invasion in NCI-H460 Human Lung Cancer Cells in Vitro
    ONCOLOGY REPORTS 34: 1853-1874, 2015 Curcumin alters gene expression-associated DNA damage, cell cycle, cell survival and cell migration and invasion in NCI-H460 human lung cancer cells in vitro I-TSANG CHIANG1,2, WEI-SHU WANG3, HSIN-CHUNG LIU4, SU-TSO YANG5, NOU-YING TANG6 and JING-GUNG CHUNG4,7 1Department of Radiation Oncology, National Yang‑Ming University Hospital, Yilan 260; 2Department of Radiological Technology, Central Taiwan University of Science and Technology, Taichung 40601; 3Department of Internal Medicine, National Yang‑Ming University Hospital, Yilan 260; 4Department of Biological Science and Technology, China Medical University, Taichung 404; 5Department of Radiology, China Medical University Hospital, Taichung 404; 6Graduate Institute of Chinese Medicine, China Medical University, Taichung 404; 7Department of Biotechnology, Asia University, Taichung 404, Taiwan, R.O.C. Received March 31, 2015; Accepted June 26, 2015 DOI: 10.3892/or.2015.4159 Abstract. Lung cancer is the most common cause of cancer CARD6, ID1 and ID2 genes, associated with cell survival and mortality and new cases are on the increase worldwide. the BRMS1L, associated with cell migration and invasion. However, the treatment of lung cancer remains unsatisfactory. Additionally, 59 downregulated genes exhibited a >4-fold Curcumin has been shown to induce cell death in many human change, including the DDIT3 gene, associated with DNA cancer cells, including human lung cancer cells. However, the damage; while 97 genes had a >3- to 4-fold change including the effects of curcumin on genetic mechanisms associated with DDIT4 gene, associated with DNA damage; the CCPG1 gene, these actions remain unclear. Curcumin (2 µM) was added associated with cell cycle and 321 genes with a >2- to 3-fold to NCI-H460 human lung cancer cells and the cells were including the GADD45A and CGREF1 genes, associated with incubated for 24 h.
    [Show full text]